Using Claims Data to Find Pharmacy Savings: The Five Reports Every Benefits Manager Should Pull Quarterly

The $400,000 Question: What Are You Missing in Your Claims Data?

Last spring, I met with the CFO of a mid-sized engineering firm. Their self-funded pharmacy plan covered 1,100 employees, and their annual pharmacy spend had quietly climbed above $1.5 million. On paper, their generic dispensing rate looked healthy at 91.7%. But when we drilled into their quarterly utilization report, one line item jumped out: thirty people were still filling brand-name insulin at $600 per script, even though a $35 authorized generic was on their formulary. This single data point, buried in report output, translated to over $400,000 in unnecessary spend each year. Nobody on the HR team had seen it. Nobody at their PBM had flagged it. This isn’t unusual. Unless you’re pulling the right claims reports, and asking the right questions, you’ll leave money on the table.

Whether you manage a 300-life plan or a 5,000-life one, the right data can make or break your pharmacy strategy. Most HR and benefits teams don’t have hours every week to dissect claims files, so you need to focus on the few reports that consistently surface opportunities for action. The five outlined below aren’t nice-to-haves, they’re foundational. Ignore them, and you’ll miss everything from biosimilar conversion opportunities to high-cost outliers using $1,200/month weight loss drugs.

Why Your 91% GDR Isn’t the Whole Story

A lot of PBMs still spotlight the generic dispensing rate (GDR) as a primary measure of plan performance. If you’re at or above the 88-92% range, you might think you’re in great shape. But I’ve seen plenty of plans with a 91% GDR still pay 60% of their total pharmacy spend on specialty drugs, or spend $60,000 a year on non-preferred brands with viable generics sitting idle. That’s because the raw GDR can hide two critical issues: gaps in generic use for high-impact classes (like insulin or ADHD meds) and a formulary that allows too many non-essential brands.

You should pull a quarterly Generic vs. Brand Utilization by Drug Class report. Don’t settle for a summary stat, get the data split by therapeutic class and ingredient. For example, in a recent review for a 900-employee school district, we found 16% of ADHD scripts were still going to branded Concerta, even though methylphenidate ER generics were available at one-sixth the cost. Switching those 14 members to generics would cut $78,000 from their annual spend. If your PBM can’t break down GDRs by class, ask for a raw claims extract and run the numbers yourself, or partner with a pharmacy benefits consultant.

For ongoing monitoring, compare your numbers with external benchmarks. Sites like RxPBM.ai and RxInfo.ai offer anonymized claims benchmarks across client types. If your mental health drug GDR trails peers by more than 3-4 points, it’s a flashing red light.

Spotting the $34,000 Humira Patient: Outlier and High-Cost Drug Reports

No plan is immune to high-cost outliers. Over the last 12 months, I’ve reviewed at least five plans where a single patient drove 8-12% of total pharmacy spend. Most often, it’s a specialty drug: Humira, Stelara, Zolgensma, or now, Wegovy. If you aren’t routinely pulling a Top 25 Highest-Cost Members and Top 50 Drug Spend reports, you might miss these entirely.

Take the case of a 2,000-life municipality in the Midwest. Their annual Humira spend exceeded $680,000, all from 19 members. What nobody realized was that four of those members were eligible for biosimilar switches at a 55% discount, and one was eligible for manufacturer assistance through their specialty pharmacy channel. A single outlier, $34,000 for one Humira patient, triggered a stop-loss claim and months of administrative hassle. Regular review of member-level and drug-level outlier reports lets you preempt those headaches.

If you find several outlier cases, don’t act impulsively. First, check for errors, such as duplicate fills or billing anomalies, a review at one manufacturer uncovered overfills worth $12,000 a quarter. Then, work with your PBM or specialty pharmacy vendor to vet switch and assistance program options. For the fast-evolving GLP-1 category (Ozempic, Wegovy, Mounjaro), check RxNews.ai for emerging coverage trends and cost projections.

Mail-Order, Step Therapy, and Other Utilization Management Reports: Are Your Controls Working?

Plan design tweaks don’t save money unless they’re consistently applied. I’ve run into plenty of employers with 90-day-at-retail or mandatory mail order for maintenance drugs on paper, only to discover, via Mail-Order Penetration and Utilization Management Overrides reports, that the real adoption rate is stuck at 18%. There’s a difference between having a step therapy edit and enforcing it.

For example, compare your mail-order penetration to industry norms, 15-25% for commercial plans, with higher rates for groups using PBMs like Express Scripts or OptumRx. If you’re at 12%, ask why. Are members opting out, or are retail pharmacies undercutting the mail rates? Are specialty drugs being processed through retail channels at higher costs?

Also, review the quarterly Step Therapy and Prior Authorization Override report. In one 500-employee manufacturer, we found 37 override approvals in a quarter, nearly all for non-preferred GLP-1s and brand-name proton pump inhibitors. Tightening these controls and checking override rationale led to $64,000 in annualized savings without significant employee pushback.

If your PBM can’t produce these reports, push them, or consider a carve-out or transparent PBM like Capital Rx or SmithRx, which often provide more granular reporting. Clinical claim reviews (see ClinicalRx.ai) can shed light on questionable overrides.

Quarterly Trend and PMPM Comparison: Are You Falling Behind?

While spot checks are valuable, you need a big-picture view of how your pharmacy spend is trending against budget and benchmarks. Pull a Quarterly Trend report showing total paid, member cost share, and plan cost, ideally broken down to the Per Member Per Month (PMPM) level. Most commercial plans land between $100 and $140 PMPM. If you see a sudden jump (say, $127 PMPM up from $103 last quarter), dig into which drug classes and utilization drivers are responsible.

A 650-employee healthcare group I advise saw PMPM spike by 18% year over year, driven mostly by GLP-1s and a handful of brand-only dermatology meds. Cross-referencing their trends against market data from RxInfo.ai helped them make the case to their executive team for a targeted step therapy policy and new exclusions, saving close to $180,000 in the first plan year. Don’t wait for renewal season to spot these trends, a quarterly cadence gives you room to intervene before costs spiral.

And don’t overlook member cost share. If your copays are flat but member OOP is rising, you may need to tweak accumulator or copay card integration. That’s a separate rabbit hole, but one where the right data flags issues before employees start complaining to HR.

Acting on the Data You Find

Pulling these five reports quarterly takes effort, but the payoff is real. You won’t catch everything in one quarter, and not every intervention will be painless. I’ve seen plans get pushback for generic step therapy changes, or for switching to biosimilars. But the employers who run these analyses and act, starting with the biggest-ticket items, consistently come out ahead, often saving six figures without cutting coverage. If you lack bandwidth or internal resources, work with a pharmacy benefits consultant or analysts who live in these data sets every day. The right reports, read with a practical eye, will do more for your bottom line than any annual PBM “savings guarantee.”